BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAF V600E) metastatic colorectal cancer (mCRC).
| Publicado en: | Journal of Clinical Oncology Vol. 40; pp. 134 - 135 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
1/6/2022 Supplement
|
| Acceso en línea: | Ver este registro en EBSCOhost |